alexsl/iStock via Getty Images
- Atara Biotherapeutics (ATRA) is off ~53% in Monday trading after the US FDA issued a Complete Response Letter for its BLA for tabelecleucel to treat Epstein-Barr virus positive post-transplant lymphoproliferative disease.
- The agency said that the single-arm ALLELE trial is